• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by HeartSciences Inc.

    7/29/25 10:21:53 AM ET
    $HSCS
    Industrial Specialties
    Health Care
    Get the next $HSCS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001016157
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HeartSciences Inc.
    SEC File Number
    001-41422
    Address of Issuer
    550 RESERVE ST, SUITE 360
    SOUTHLAKE
    TEXAS
    76092
    Phone
    682-237-7781
    Name of Person for Whose Account the Securities are To Be Sold
    HILZ MARK T
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    THE CHARLES SCHWAB CORPORATION
    3000 Schwab Way
    Westlake � TX � 76262
    441615720.96193428007/29/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON12/08/2014PURCHASEISSUERCheckbox not checked441612/08/2014N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/29/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/18/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    MARK HILZ

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HSCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HSCS
    SEC Filings

    View All

    HeartSciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - HeartSciences Inc. (0001468492) (Filer)

    8/22/25 4:09:29 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by HeartSciences Inc.

    424B5 - HeartSciences Inc. (0001468492) (Filer)

    8/4/25 8:34:19 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - HeartSciences Inc. (0001468492) (Filer)

    8/4/25 8:30:37 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Heart Test Laboratories Inc.

    SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

    12/11/23 8:30:12 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Heart Test Laboratories Inc.

    SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

    11/27/23 4:02:41 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form SC 13D filed by Heart Test Laboratories Inc.

    SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

    6/14/23 5:06:17 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Financials

    Live finance-specific insights

    View All

    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

    Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements during fiscal year 2025, marking a pivotal shift in its strategy to enhance the clinical value of ECGs through AI and cloud-based technologies that can be deployed across diverse healthcare settin

    7/24/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

    Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) --  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host

    10/19/23 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    HeartSciences Announces Conference Participation and Investor Webinar

    Southlake, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its participation in multiple virtual events during the month of August. These events are intended to further introduce HeartSciences' technology and update investors and interested stakeholders. The Company will be hosting an Investor Webinar on Wednesday, August 20, 2025, at 2:00 p.m. Eastern Time. The virtual event will provide an overview of the Company's mission, market opportunity, and recent progress. All i

    8/15/25 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO, Secretary and Director Hilz Mark T sold $15,621 worth of shares (4,416 units at $3.54), decreasing direct ownership by 48% to 4,752 units (SEC Form 4)

    4 - HeartSciences Inc. (0001468492) (Issuer)

    7/30/25 9:00:03 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Bent Bruce

    4 - HeartSciences Inc. (0001468492) (Issuer)

    7/14/25 9:02:04 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Officer Hilz Mark T

    4 - HeartSciences Inc. (0001468492) (Issuer)

    7/11/25 9:00:02 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

    Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

    5/7/25 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Adds Key Advisor to its Scientific Advisory Board

    Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has

    2/26/24 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Expands its Scientific Advisory Board

    Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi

    2/12/24 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care